COSTAR II: CObalt chromium STent with Antiproliferative for Restenosis II Trial

Study of:
The purpose of this study is to evaluate the safety and effectiveness of the investigational drug-filled COSTAR™ Paclitaxel-Eluting Coronary Stent in comparison to an approved drug-eluting stent (TAXUS Express 2™ Paclitaxel-Eluting Coronary Stent) in the treatment of single- and multi-vessel coronary artery disease. Both the TAXUS and the COSTAR stents deliver the drug paclitaxel, a drug to prevent scar tissue (reblockage). The COSTAR stent is different from currently approved drug eluting stents because the stent is not coated with the drug; rather, the drug is placed in small holes throughout the structure of the stent. Follow-up includes a visit at 1 and 8 months. Also, the first 200 multi-vessel patients and the first 150 single-vessel patients will undergo an angiogram at 9 months.

• Michael R. Mooney, MD, FACC

• M. Nicholas Burke, MD
• Ivan J. Chavez, MD, FACC
• Timothy D. Henry, MD, FACC
• Daniel Lips, MD, FACC
• James D. Madison, MD, FACC
• Wesley R. Pedersen, MD, FACC
• Anil K. Poulose, MD, FACC
• Jay H. Traverse, MD, FACC, FAHA
• Yale Wang, MD, FACC, FSCAI

• Gretchen Peichel, RN

For more information about this study or the Interventional Cardiology Research program at the Minneapolis Heart Institute Foundation, please contact Carol Stone at 612-863-9124.